
Data Collection & Advocacy
A few words on Skyhawk’s Phase 1c interim results – SKY-0515 in Huntington’s disease
Dr. Ignacio Muñoz-Sanjuan, Factor-H president, shares in this article his first insights on the Skyhawk’s Therapeutics announcement from January 28.


